Advances in rituximab treatment of refractory myasthenia gravis
10.3760/cma.j.issn.1673-4408.2018.10.008
- VernacularTitle:利妥昔单抗在难治性重症肌无力中的研究进展
- Author:
Quanmei XU
1
Author Information
1. 200062,上海市儿童医院 上海交通大学附属儿童医院神经内科
- Keywords:
Refractory myasthenia gravis;
Rituximab
- From:
International Journal of Pediatrics
2018;45(10):772-775
- CountryChina
- Language:Chinese
-
Abstract:
Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused by circu-lating antibodies specific for the post-synaptic receptor. It results in neuromuscular transmission disorders. After optimal treatment with standard drugs,most myasthenia gravis patients can achieve a good life quality. Part of patients cannot get stable clinical remission or minimal manifestation with standard therapy. Rituximab is a chim-eric mouse/human antibody specific for the CD20 B-cell surface antigen. Studies have showed that rituximab is effective in the refractory myasthenia gravis. This review mainly discusses about the advances of rituximab in the treatment of refractory myasthenia gravis.
